Hunter et al. engineer a high affinity, soluble variant of leukemia inhibitory factor receptor (LIFR) to serve as a ligand trap for the LIF cytokine. They further demonstrate that this engineered LIFR exhibits improved affinity relative to the wild-type receptor, leading to better disruption of LIF signaling in cancer cells, and highlighting promise of such ligand traps as therapeutic strategy for cancer treatment.
- Sean A. Hunter
- Brianna J. McIntosh
- Jennifer R. Cochran
